Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz purchased 9,070 shares of the stock in a transaction dated Monday, September 9th. The stock was bought at an average cost of $11.02 per share, with a total value of $99,951.40.
MIRM traded down $0.05 during trading on Wednesday, hitting $10.13. 3,576 shares of the company’s stock traded hands, compared to its average volume of 45,832. The business’s 50 day moving average is $13.15. Mirum Pharmaceuticals has a 12-month low of $9.25 and a 12-month high of $15.50.
Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, August 28th. The company reported ($2.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($1.83). Equities analysts expect that Mirum Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Further Reading: The Structure of a Futures Contract
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.